INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages ofpamphlets pubhshing international appli¬ cations under the PCT.

AT Austria FR France ML Mali

AU Australia GA Gabon MR Mauritania

BB Barbados GB United Kingdom MW Malawi

BE Belgium HU Hungary NL Netherlands

BG Bulgaria IT Italy NO Norway

BJ Benin JP Japan RO Romania

BR Brazil KP Democratic People's Republic SD Sudan

CF Central African Republic of Korea SE Sweden

CG Congo KR Republic ofKorea SN Senegal

CH Switzerland LI Liechtenstein SU Soviet Union

CM Cameroon LK Sri Lanka TD Chad

DE Germany, Federal Republic of LU Luxembourg TG Togo

DK Denmark MC Monaco US United States of America

FT Finland MG Madagascar

ANTITUMOR CYCLOHEXANONE COMPOSITONS AND DERIVATIVES THEREOF

Field of the Invention

This invention relates to new cyclic organic compounds which have useful antitumor activity. More particularly/ this invention relates to new cyclohexanone and cyclohexanone derivative antitumor compositions derived from marine organisms, i.e., the acorn worm, Ptychodera sp.

Background of the Invention

Various tumor related diseases inflict man. Considerable research has been devoted to oncology and antitumor measures. Tumors are common in a variety of mammals and the prevention, control of the growth and regression of tumors in mammals is important to man. The term tumor refers to abnormal masses of new tissue growth which is discordant with the economy of the tissue of origin or of the host's body as a whole. Tumors inflict mammals and man with a variety of disorders and conditions including various forms of cancer and resultant cancerous cachexia. Cancerous cachexia refers to the symptomatic discomfort that accompanies the infliction of a mammal with a tumor. These symptoms include weakened condition of the inflicted mammal as evidenced by, for example, weight loss. The seriousness of cancer is well known, e.g., cancer is second only to heart and vascular diseases as a cause of death in man.

^β Considerable research and resources have been devoted to oncology and antitumor measures including chemotherapy. While certain methods and chemical compositions have been developed which aid in inhibiting, remitting or controlling the growth of 5 tumors new methods and antitumor chemical compositions are needed.

Various new six membered ring organic compounds which have been reported to have or potentially have antitumor and antibiotic activity 0 have been isolated from bacteria and mold. Compounds of particular interest are described in the following references: V-aminoepoxysemiquinone is disclosed by M.D. Lee, et al., "New Antitumor Antibiotic, LL-Cl0037a Fermentation, Isolation and Structure -5 Determination", The Journal of Antibiotics, Vol. 37, No. 10, pp. 1149-1152 (October 1984); 4-amino-7-oxa-bicyclo[4, 1, 0] hept-3-ene-2, 5-dione-3-carboxamide is disclosed by G.C.S. Reddy, et al., "Stereochemistry of the Epoxydon Group 0 Antibiotic G7063-2 Isolated From A STREPTOMYCES

Species HPL Y-25711", The Journal of Antibiotics, Vol. 37, No. 12, pp. 1596-1599 (December 1984); various other compounds are described in M.W. Miller, "The Structure of Terremutin," Tetrahedron, Vol. 24, pp. 4839-4851 (1968); and A. Closse, et al. , Helv.

Chim. Acta, Vol. 49, p. 204 (1966). The entire disclosures of the above-mentioned references are hereby incorporated herein by reference. While these references show compounds which may have antibiotic

^β and antitumor application, the need exists for new compounds which display a favorable amount of antitumor activity.

It has now been found that certain six membered ring organic compounds derived from extracts 5 of the acorn worm, Ptychodera sp. possess useful antitumor activity.

Summary of the Invention

0 It is therefore an object of the invention to provide novel compositions which are useful as antitumor agents and a process for producing such novel antitumor compositions.

Additional objects and advantages of the *5 invention will be set forth, in part, in the description which follows and in part will be obvious from this description, or may be learned by the practice of the invention. The objects and advantages of the invention are realized and obtained 0 by means of the compositions, processes, nethods, and the combinations particularly pointed out in the appended claims.

To achieve the objects in accordance with the purposes of the invention, as embodied and fully ^* 5 described here, the invention comprises compositions

0

of the general formulae (I-IV)

II III IV

1 2 wherein X and X are the same or different and

1 2 are a halogen, hydroxy, or hydrogen; R, and R are selected from the group consisting of hydroxy, lower acyloxy and lower alkoxy.

In preferred embodiments of the invention, the composition is substantially pure and X or

2 1 is bromine, R is a lower acyloxy or alkoxy which has from 1 to 4 carbon atoms . In more preferred embodiments of the invention, the invention comprises compositions of the formulae (V-IX):

VI

ocoαc

VII viπ

As embodied and fully described herein, the invention also comprises an antitumor composition comprising, as active ingredient, an effective antitumor amount of one or more compositions according to formulae I-IX and a non-toxic pharmaceutically acceptable carrier or diluent.

As embodied and fully described herein, the invention also comprises a process to produce the compounds of formulae I-IX. The process comprises the steps of collecting acorn worm, Ptychodera, sp., contacting the acorn worm with a suitable organic solvent; homogenizing the acorn worm and solvent mixture to obtain an extract thereof; and isolating a compound according to formulae l-ix from the extract. In preferred embodiments of the invention the suitable organic solvent is selected from the group consisting of acetone, methyl ethyl ketone, ethyl acetate, methanol, ethanol, and methyl isobutyl ketone.

As embodied and fully described herein, the invention further comprises a method for inhibiting tumors in a host and a therapeutic method for treating cancerous cachexia comprising contacting a tumor with an effective antitumor amount of one or more compositions of formulae I-IX. It is to be understood that both the foregoing general and che following detailed description are exemplary and explanatory only and are not intended to be restrictive ^' of the invention as claimed.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Reference will now be made in detail to present preferred embodiments of the invention, examples of which are illustrated in the following example section.

In accordance with the invention novel compositions are provided to achieve the objects in accordance with the purposes of the invention, as embodied and fully described herein, the invention comprises compositions of the general formulae (I-IV)

∑i III IV wherein X 1 and X2 are the same or different and are a halogen, hydroxy, or hydrogen; R, 1 and R2 are selected from the group consisting of hydroxy, lower acyloxy and lower alkoxy.

In preferred embodiments of the invention, the composition is substantially pure and X or

X 2 is bromine, R1 is a lower acyloxy or alkoxy having from 1 to 4 carbon atoms. In more preferred embodiments cf the invention, the invention comprises

compositions of the formulae (V-IX)

VI

In accordance with the invention, an antitumor composition is provided comprising as active ingredient an effective antitumor amount of one or more of the compositions described above and identified by formulae I-IX in a non-toxic pharmaceutically acceptable carrier or diluent. While effective amounts may vary, as conditions in which the antitumor compositions are used vary, a minimal dosage required for activity is generally between 0.01 and 100 micrograms against 10 tumor cells. Useful examples of non-toxic pharmaceutically acceptable carriers or diluents include, but are not limited to, the following: ethanol, dimethyl sulfoxide and glycercl.

In accordance with the invention, a method for inhibiting tumors in a host is provided comprising contacting a tumor with an antitumor amount of one or more compositions according to formulae I-IX. The effectiveness of the compositions of the invention for inhibiting tumors indicates

their usefulness for controlling tumors in hosts including mammals and for treating cancerous cachexia.

In accordance with the invention, a process to produce a compound according to formulae I-IX comprises the step of: collecting acorn worm Ptychodera sp.; contacting the collected acorn worm with a suitable organic solvent; homogenizing the solvent and acorn worm mixture to obtain an extract of the solvent; and isolating a compound according to formulae I-IX. A detailed description and explanation of a preferred embodiment of the process of the invention to produce the compound according to formulas l-ix is as follows: acorn worm Ptychodera sp., is collected from submarine caves in the vicinity of Maui, Hawaii. The acorn worm is homogenized with acetone (a first solvent) in a mortar or blender. The acetone extract is concentrated and partitioned between water (a second solvent) and methylene chloride (a third solvent) to give an organic residue. The residue is grossly separated into fractions which yield various compositions. Compositions according to the invention are isolated by various chromatographic techniques from the fractions obtained. While acetone, water and methylene chloride are the presently preferred choices for the first, second and third solvents, respectively, other suitable solvents may be substituted. A suitable first solvent should be capable of extracting ^" a compound according to any one of formulae I-IX from other components of the acorn worm. Suitable first solvents which may be substituted for acetone

o include, but are not limited to, the following organic solvents: methyl ethyl ketone; ethyl acetate; methanol; ethanol; and methyl isobutyl ketone. Suitable second and third solvents should be capable of extracting and separating into various - fractions the various compounds of formulae I-IX from other components that may be present in the first solvent extract. Suitable second and third solvents which may be substituted for either water or methylene chloride or both include, but are not Q limited to either water or methylene chloride alone or, the following organic solvents: chloroform; trichloroethylene; hexane, and lower alkanes. Different ratios of first, second and third solvents and any combination may be used in the invention as 5 would be known to those skilled in the art.

Any suitable fractionation and isolation techniques may be utilized in accordance with the process of the invention. Suitable fractionation techniques include various chromotography techniques Q such as, high pressure liquid chromatoσraphy (HPLC) with a suitable column as would be known to those skilled in the art (e.g., a Whatman partisil column (M9 50/10) eluted with a suitable solvent such as, for example, 4:1 to 2:1, hexanes: ethyl acetate. 5 It is therefore apparent that the compositions of the invention, the processes for producing che compositions of the invention and the methods for utilizing the compositions of the invention to inhibit tumors are effective for 0 inhibiting or destroying tumors and therefore controlling diseases caused by or related to such tumors in fulfillment of the objects of the invention.

EXAMPLES

The invention will now be illustrated by examples. The examples are not intended to be limiting of the scope of the present invention. In conjunction with the detailed and general description above, the examples provide further understanding of the present invention and outline a process for producing compositions of the invention.

The following examples represent preferred embodiments of the compositions, processes and methods of the invention for satisfying the stated objects of the invention. The starting materials and reagents in the examples whose method of preparation are not indicated are commercially available from sources known to the art such as chemical supply ^• houses.

Examples 1-5

Acorn worm, Ptychodera sp., 294 g s (wet weight with a minor amount of silt) was collected from submarine caves of Maui, Hawaii and was homogenized with acetone in a mortar. The acetone extract (800 ml) was concentrated and partitioned between water and CH ₂ Cl ₂ , (3x200 ml)to give 740 mg of organic residue. The residue was grossly separated on a silica gel (25 g) column (2:1 hexanes-EtOAc) into 15 fractions. Elution volume and yield of each fraction are shown in Table 1.

o

Table 1. Gro__ Separation of the Extract o_ Ptychodera a-

Fr.# Elatioa Yield Fr.# Elatioa Yield Pr.# Elatioa Yield Vol.(ιιl) (αg) Vol. (ml) (ag) Vol.(al) (mg)

1 20 57 6 20 47 11 40 7.9

2 20 121 7 20 35 12 20 2.5

3 20 108 8 20 15 13 40 11.2

4 20 45 9 20 7.9 14 40 8.6

5 20 78 10 20 4.9 15 300 11.4

Each of the fractions 1-12 was separated by HPLC with a Whatman Partisil column (M9 50/10) by eluting with 4:1 to 2:1 hexanes: ethylacetate. Yields of major constituents are shown in Table 2.

Table 2. Yields of Compounds Isolated from Ptvchodera sp.

Compound # 1 2 3 4 5 Yield (mg) 56.2 19.0 S.5 24.1 67.6

. Example 1

[4S,5R,6R]-4-Acetoxy-2-bromo-5, 6-epoxy-2-cyclohexanone

Preparation of:

(1)

It Compound (1) was obtained from fractions

2-8. Recrystallization of the HPLC-separated sample from hexanes-EtOAc gave colorless needles, p 93-94°- [OC.i ⁹ +265° (c 0.12, CHC1 ₃ ,). HRMS m/z 245.9542 (calcd. for C _Q Hy Brθ ₄ 245.9528). EIMS m/z 248 (3.7), 246 (3.9), 206 (25), 204 (25), 190 (3.7), 188 (3.4), 178 (11), 176 (11), 177 (15.4), 175 (15.9), 161 (11.3), 159 (12.8), 133 (12.3), 131 (13.7), 125 (13.2), 107 (10.1), 97 (33.3), and 43 (100%). IR (KBr) 1730, 1700, 1615, 1375, 1240, 1210, 1030, 970, 910, and 780 cm - ¹ . ^X H NMR (CDCl- _j ) /7.04 (IH, dd, J=5.3, 2.3 Hz), 5.73 (IH, dt, J=5.3, 1.3 Hz), 3.75 (IH ddd, J=3.4, 2.3, 1.3 Hz), 3.68 (IH, dd, J=3.4, 1.2 HZ), and 2.13 (3H, s) .

Example 2 [4S, 5R, 6S.-4-Acetoxy-2,6-dibromo-5hydroxy— cyclohexanone (2)

Preparation of:

OCOCH

(2)

o This compound was contained in fractions

4-12 and was isolated in 19 mg. Purification by HPLC gave 15.1 mg of glass which solidified during storage in a freezer. Recrystallization from hexane-ethyl acetate gave colorless crystals, p 136-138°. HRMS

5 m/z 325.8823 _+ 0.0326 (calcd for CgH-Br-O.

325.8789); EIMS m/z 330, 328, 326 (M ), 288, 286,

284 (M-C ₂ H ₂ 0), 270, 268, 266 (M-C ₂ H-.0

-H ₂ 0), 249, 247 (M-Br), 231, 229 (M-Br, -F _j O) ,

207, 205 (M-Br, -C ₂ H ₂ 0), 206, 204 (M-Br, -C ₂ H ₃ 0), 189, 187 (M-Br, -C ₂ __ ₂ 0 ~H ₂ 0), 164

162, 158, 126, 125, 97, 53, 51, and 43 (base); UV

_—ma„x{-_eOH) 255 (£ 5200); IR (KB-r) -3430, 2920, 1725,

1700, 1607, 1218, and 1043 cm ^"1 ; ¹ H NMR (CDCl ₃ ) 7.22 (IH, d, J=2.4 Hz), 5.63 (IH, dd, J=8.2, 2.4 Hz), 4.67 (IH, d, J=ll.l Hz), 4.17 (IH, ddd, J-=ll.l, 8.2, 2.7 Hz), 3.02 (IH, d, J=2.7 Hz, D ₂ 0 exchangeable), and 2.18 (3H, s); ¹³ C NMR (CDC1 ₃ ) Λ46.0, (C-3), 122.7 (C-2), 74.6 (C-4),

72.7 (C-5), 56.7 (C-6), and 20.8 (CH 3).

Example 3

4-Acetoxy-2-bromo-5 ,6-epoxy-3- hydroxycyclohexanone(3)

Preparation of:

OCOCH.

_

(3)

An additional HPLC purification of the 8.5 mg sample obtained from fractions 4-12 was carried out and gave an oil ^H NMR (CDCl-) 5.31 (IH, dd, J-5.1, 2.9 Hz), 4.96 (IH, d, J=2.5 Hz), 4.16 (IH, m), 3.81 (IH, t, 3.1 Hz), 3.56 (IH, d, J-3.6 Hz), 2.62 (IH, d, J=5.5 Hz), and 2.20 (3H, s).

Example 4 [3S, 4R, 5S, 6R]-3-Acetoxy-l,5-dibromo-4,6-dihydroxycy clohexene

Preparation of:

(4)

The compound was contained in fractions 5-12 and isolated as an oil in total 24.1 mg slightly contaminated with other products. Crystallization from 2:1 hexanes-EtOAc gave colorless crystals, mp 150.5-151.5°. HRMS m/z 232.9628 [ ⁺ -H ₂ 0, -Br), calcd. for CgHg 81 BrO- 232.9636], 205.9590

(calcd. for C _g H ₇ 79B. rO ^J -. 205,9579), and

190.9523 (calcd. for C.Hg ⁸¹ Br0 ₂ 190.9531).

EIMS m/z 233 (29), 231 (29), 208 (19), 206 (20), 191

(99), 189 (96), 166 (52), 164 (52), 110 (100), 109

(62), 82 (20), 80 (15), and 43 (94). IR (KBr) 3420,

1720, 1365, 1285, 1240, 1105, 1080, 1045, and 1025

„ cm ^"1 . ¹ H NMR (CDC1 ₃ ), β.10 (IH, d, J=2.7 Hz),

5.27 (IH, dd, J=7.0, 2.7 Hz), 4.47 (IH, dd, J=3.4, 3.3 HZ), 4.25 (IH, dd, J=11.4, 3.3 Hz), 4.17 (IH, dd. Jell.3, 7.1 Hz), 2.77 (IH, d, J=3.7 Hz), 2.64 (IH, bs) , and 2.11 (3H, s) .

5

Example 5

[4S,5R,6R3-4-Acetoxy-2,6-dibromo-5- hydroxy-2-cyclohexenone (5)

Preparation of

The compound (5) was most abundant and obtained from fractions 4-12 in total 67.6 mg. A part of the sample was repurified by HPLC to give a glass which solidified during storage in a freezer. An attempt to recrystallize the solid from cyclohexane-benzene was unsuccessful, presumably because of partial epimerization of the compound to compound 2 (above). Optical rotation of the pure 5 sample was recorded as fα_]_ D23 + 130° (c 0.1,

CH ₂ C1 ₂ ). HRMS m/z 325.3823 (calcd for

CgH ₈ Br ₂ 0 ₄ 325.8789); EIMS m/z 330, 328, 326,

288, 286, 284, 270, 268, 266, 249, 247, 231, 229,

207, 205, 189, 187, 164, 162, 161, 159, 126, 125, 97, 0

53 , 51 , and 43 ( base ) ; ϋv λ — ul _a α _v X ( MeOH ) 256 ( ^' 5500 ) and 202 n ( ζ 4200); IR (KBr) 3430, 2920, 1720, 1700, 1605, 1370, 1215, 1090, and 1040 cm ^"1 ; ¹ H NMR (CDC1 ₃ )/7.18 (IH, d, J=2.7 Hz), 5.61 (IH, dd, J=7.4, 2.7 Hz), 4.77 (IH, d, J=3.5 Hz), 4.06 (IH, br dd, J=7.4, 3.5 Hz), 2.88 (IH, br s, D ₂ 0 exchangeable), and 2.18 (3H, s); ¹³ C NMR (CDC1-) 145.2 (C-3), 72.7 (C-5), 71.6 (C-4), 52.3 (C-6), and 20.8 (CH ₃ ).

10 ANTITUMOR ACTIVITIES OF THE COMPOUNDS OF THE INVENTION

The following assay method was utilized to illustrate the antitumor effectiveness of the compositions of Formulae I, II, and IV corresponding • _j e to compositions 1, 2 and 4 of the examples.

L1210 And P388 MOUSE LEUKEMIA CELL CYTOXICITY ASSAY 24-WELL PLATE SCREENING ASSAY AND TUBE ASSAY PROTOCOL

20 MATERIALS UTILIZED

Media - Dulbeccos with glucose and pyruvate (Biologos, Inc) with 10% horse serum, (Biologos, Inc) and 1.0 ug/ l gentamicin (Gibco) .

2 Cells - L1210 and P-388 mouse leukemia cells

(American Type Culture Collection) and A549 human lung HCT-8 human colon and CF-7 human breast cells in media at a concentration of

5x10 cells/ml. Sterile 24-well culture 0

o plates (Nunc) for screening or 12 x 75mm glass culture tubes (Becton-Dickinson) for tube assay. Microdispenser with 1 to 5 ul increments (Drummond Scientific Co. Broomall PA). Finnpipette with 5 to 50 ul increments and

Finnpipette with 50 to 200 ul increments.

PROCEDURE

1. A sample of the composition to be assayed is added to each well or tube in an amount of from 200 ug/ml and 100 ug/ml for screening. For DDC of known active compounds use log concentrations from 100 ug/ml to .01 ug/ml for range-finding assay; when range has been determined, use five concentrations between highest and lowest active concentrations.

4

2. Add 2.0 ml of 5 x 10 cell suspension in media to each well or tube. Tubes are loosely covered with parafilm.

3. Incubate in 5% C0 ₂ incubator 48 hours.

4. Visually read plates with inverted microscope, comparing with solvent control. Assign activity as follows:

0 = 90 - 100% of control growth

1+ = 75 - 89% of control growth 2+ = 50 - 74% of control growth

o 3+ = 25 - 49% of control growth

4+ = 25% of control growth

Repeat all positive samples using tube assay.

5. For Tube assays - Mix tube well on vortex and remove 0.5 ml aliσuot and add to

9.5 ml nf diluent fluid (Isoton - Coulter) in Accuvette (Coulter) and mix well by inversion immediately before counting, taking care not to produce excessive bubbles. Count on Coulter Counter (Counter is set to count 0.5 ml of the solution; therefore counts may be converted to cll/ml in original assay tube by multiplying count ' by 40.

Positive control - Vinblastine or Vincristine in aqueous solution.

Final Cone, of Vinblastine or Vincristine control (use 2 ul/assay)

Final cone. Solution Cone. Amt added in test

10 mg/ml 2 ul 10 ug/ml

1 mg/ml 2 ul 1 ug/ml

0.1 mg/ml 2 ul 0.1 ug/ml

0.01 mg/ml 2 ul 0.001 ug/ml

Notes:

For solvents other than water, allow solvent to evaporate from tube or well in hood.

" Chloroform and butanol cannot be used in the plastic 24-well plates - use glass tubes.

Always run a solvent control in duplicate in the last two wells of each plate or four tubes for each rack of 72 or less tubes. Also run four wells or tubes with media and cells only per run of plates or tubes. When using volumes of aqueous solutions greater than 200 ul, dry sample and bring up to desired concentration in media.

The results of the above assay are summarized below in Table 3. Compounds of formulae I/l; II/2; and IV/4 are cytotoxic _irι vitro against P-388 murine leukemia cells; L-1210 murine leukemia cells; A549 human lung cells ^' ; HCT-.8 human colon cells; and MCF-7 human breast cells.

Table 3 Antitumor Assay Results

Compound

Formula/Example Concentration P388 L1210

I/l 100 ug/ml 3+

10 4+ 4+

0.1 3+ 2+

0.01 2 + 1+

II/2 100 3+

10 3+

1 2+

IV/4 100 4+

10 4+ I 3+

A549 HCT-8 ^' MCF-7

I/l 50 ug/m L 4+ 4+

20 4+ 4+

10 4+ 4+ 4+

5 4+ 4+

1 ND 3+ 3+

0.5 ND

0.1 2+

0.01 ND

II/2 50 ug/ml ND

5 ND

IV/4 50 4+ 5 ND

The scope of the present invention is not limited by the description, examples, and suggested uses herein and .modifications can be made without departing from the spirit of the invention. For example, it may be noted that other derivatives of the compounds of examples 1-5 such as a fluorinated derivative may possess antitumor activity analogous to- those preferred embodiments described above. Further, the compositions described herein may have other useful applications such as, for example, analgesic applications. Application of the compositions of the present invention can be accomplished by any suitable therapeutic method and technique as is presently or prospectively known to those skilled in the art. Thus, it is intended that the present invention cover the modifications and variations of this invention provided that they come within the scope of the appended claims and their eσuivalents.